Curaleaf Reports Strong Q2 2026 Growth with 10% Revenue Increase
Event summary
- Curaleaf reported Q2 2026 net revenue of $340 million, up 10% year-over-year.
- International revenue grew 26%, while domestic revenue increased 7%.
- Gross profit margin was 50%, and adjusted EBITDA was $70 million.
- Completed buyout of remaining 45% equity interest in Four20 Pharma, increasing ownership to 100%.
- Expanded retail footprint in Florida to 73 dispensaries.
The big picture
Curaleaf's Q2 2026 results highlight its 'Built for Growth' strategy gaining traction. The company's focus on customer centricity, brand building, and operational excellence is reflected in the strong revenue growth and margin strength. The international segment's significant growth underscores the potential of Curaleaf's global expansion efforts.
What we're watching
- Domestic Momentum
- Whether Curaleaf can sustain its second consecutive quarter of domestic year-over-year growth.
- International Expansion
- The pace at which Curaleaf's international segment will continue to grow, particularly in Europe.
- Regulatory Approvals
- How the DEA registration process for medical cultivation, processing, and dispensing locations will impact operations.
Related topics